Cyclacel Pharma (CYCC) Reports Q2 Loss of $1.19

Cyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($1.19), versus ($1.01) reported last year. Revenue for the quarter came in at $296 thousand, versus $222 thousand reported last year.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Evogene (EVGN) Tops Q2 EPS by 15c
• XP Inc. (XP) Tops Q2 EPS by 8c